Skip to main content

Table 2 Frequency of hypertension, dyslipidemia, and use of medication in patients with and without Takayasu’s arteritis activity

From: Endothelial progenitor cells and vascular endothelial growth factor in patients with Takayasu’s arteritis

Variables Without activity N = 21
N (%)
With activity N = 9
N (%)
p
Hypertension 16 (76.2) 07 (77.8) 1.00
Dyslipidemia 12 (57.1) 06 (66.7) 0.704
Statins 11 (52.4) 05 (55.6) 1.00
ACE inhibitors 10 (47.6) 05 (55.6) 1.00
ARB 02 (9.5) 01 (11.1) 1.00
Beta-blockers 05 (23.8) 04 (44.4) 0.389
Calcium channel blockers 05 (23.8) 03 (33.3) 0.666
Acetyl salicylic acid 21 (100) 09 (100) 1.00
Prednisone 16 (76.2) 07 (77.8) 0.166
Dose ≤5 mg: 06 (37.5) Dose ≤5 mg: 0
Dose > 5 mg: 10 (62.5) Dose > 5 mg: 07 (100)
Immunosuppressive drugs 17 (80,9) 07 (77,7) 1,00
Leflunomide: 06 (35) Leflunomide: 05 (71,4) 0,225
Methotrexate: 09 (53) Methotrexate: 01(14,2) 0,204
Azathioprine: 02 (12) Azathioprine: 01 (14,2) 1,00
users of anti-TNF 03 (14,2) 02 (22,2) 0,622
  1. ACE angiotensin-converting enzyme, ARB angiotensin receptor blocker
  2. TNF tumor necrosis factor